For this validation assay, we selected three different drugs for which PTEN was enriched: Vorinostat (HDAC inhibitor), which is given as a treatment for cutaneous T cell lymphoma (CTCL48); Ibrutinib, a tyrosine kinase inhibitor used as a treatment for chronic lymphocytic leukaemia and various lymphomas49; Finally, enzalutamide is a relatively new anticancer drug used for the treatment of prostate cancer,50 via an androgen receptor (AR) signalling pathway. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.